Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BotuCiSter sternotomy scar prevention trial
2025-521290-14-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in surgical scar and Skin and connective tissue disease (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Stony Brook Scar Evaluation Scale at 6 months. Planned start Aug 2025; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
surgical scarSkin and connective tissue disease
Beyond the preview
Go deeper on 2025-521290-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521290-14-00.